FocalTherics

FocalTherics is a preclinical-stage biotechnology company developing a platform for the localized delivery of therapeutics to treat inflammatory diseases, with an initial focus on the gastrointestinal tract. Founded by pioneers from MIT and Harvard, the company's technology aims to deliver high concentrations of drugs directly to diseased tissue while minimizing systemic exposure and side effects. Their lead program targets ulcerative colitis, utilizing a novel delivery mechanism to provide targeted relief at the site of inflammation. By decoupling local efficacy from systemic toxicity, FocalTherics seeks to transform the treatment landscape for chronic inflammatory conditions. The company is a spin-out from the laboratories of Michael Cima, Robert Langer, and Giovanni Traverso.